Who are NeoGenomics, Inc.'s main suppliers?

NeoGenomics, Inc. (NEO) key suppliers include: Exact Sciences Corp, Exact Sciences Corp, Guardant Health, Inc., Guardant Health, Inc., Myriad Genetics, Inc. and 3 more. View the full supplier network at chainsifter.com/chain/NEO.

Who are NeoGenomics, Inc.'s major customers?

NeoGenomics, Inc. (NEO) key customers include: OTHER-CROS, PHARMACEUTICAL-AND-BIOTECH-CLIENTS, ACADEMIC-CENTERS, COMMUNITY-BASED-PATHOLOGY-AND-ONCOLOGY-PRACTICES, HOSPITAL-PATHOLOGY-LABS and 17 more. View the full customer network at chainsifter.com/chain/NEO.

What sector is NeoGenomics, Inc. in?

NeoGenomics, Inc. (NEO) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NEO Supply Chain: NeoGenomics, Inc. Supplier List & 33 Relationships

8Suppliers

22Customers

3Debt Items

20Related Chains

NeoGenomics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
EXAS	Exact Sciences Corp	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
EXAS	Exact Sciences Corp	72%	Reciprocal relationship from EXAS graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities…
GH	Guardant Health, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
GH	Guardant Health, Inc.	72%	Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities i…
MYGN	Myriad Genetics, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities…
TEM	Tempus AI, Inc.	72%	Reciprocal relationship from TEM graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities …
TEM	Tempus AI, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …

NeoGenomics, Inc. Customers

Ticker	Name	Confidence	Evidence
OTHER-CROS	OTHER-CROS	92%	For the Company's pharmaceutical development services, the Company generally enters into contracts with pharmaceutical and biotech clients as well as other CROs to provide research and clinical trial…
PHARMACEUTICAL-AND-BIOTECH-CLIENTS	PHARMACEUTICAL-AND-BIOTECH-CLIENTS	92%	For the Company's pharmaceutical development services, the Company generally enters into contracts with pharmaceutical and biotech clients as well as other CROs to provide research and clinical trial…
ACADEMIC-CENTERS	ACADEMIC-CENTERS	90%	The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical …
COMMUNITY-BASED-PATHOLOGY-AND-ONCOLOGY-PRACTICES	COMMUNITY-BASED-PATHOLOGY-AND-ONCOLOGY-PRACTICES	90%	The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical …
HOSPITAL-PATHOLOGY-LABS	HOSPITAL-PATHOLOGY-LABS	90%	The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical …
INDIVIDUAL-INSURANCE-COMPANIES	INDIVIDUAL-INSURANCE-COMPANIES	90%	Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to which we provide a significant volume of our services, and to specific payers…
MEDICARE	MEDICARE	90%	Concentrations of credit risk with respect to revenue and accounts receivable are primarily limited to certain clients to which we provide a significant volume of our services, and to specific payers…
PHARMACEUTICAL-COMPANIES	PHARMACEUTICAL-COMPANIES	90%	The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical …
REFERENCE-LABS	REFERENCE-LABS	90%	The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical …
PATIENTS	PATIENTS	85%	These clinical services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients.
PAYERS	PAYERS	85%	These clinical services are billed to various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients.
EXAS	Exact Sciences Corp	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
EXAS	Exact Sciences Corp	72%	Reciprocal relationship from EXAS graph: Reciprocal relationship from NEO graph: Reciprocal relationship from EXAS graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic …
GH	Guardant Health, Inc.	72%	Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities i…
GH	Guardant Health, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
MYGN	Myriad Genetics, Inc.	72%	Reciprocal relationship from MYGN graph: Reciprocal relationship from NEO graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from NEO graph: Reciprocal relationship from MYGN gra…
MYGN	Myriad Genetics, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
TEM	Tempus AI, Inc.	72%	rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory testing industry, we expect competition to …
TEM	Tempus AI, Inc.	72%	Reciprocal relationship from TEM graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities …
CARIS-LIFE-SCIENCE-TEMPUS-LABS-INC	CARIS-LIFE-SCIENCE-TEMPUS-LABS-INC	62%	. The market for genetic and molecular testing services is highly competitive, and, given the opportunities in this market within the laboratory testing industry, we expect competition to continue in…
GUARDANT-HEALTH-INC-NATERA-INC-EXACT-SCIENCES-CO	GUARDANT-HEALTH-INC-NATERA-INC-EXACT-SCIENCES-CO	62%	. The market for genetic and molecular testing services is highly competitive, and, given the opportunities in this market within the laboratory testing industry, we expect competition to continue in…
QUEST-DIAGNOSTICS-LABORATORY-CORPORATION	QUEST-DIAGNOSTICS-LABORATORY-CORPORATION	62%	. The market for genetic and molecular testing services is highly competitive, and, given the opportunities in this market within the laboratory testing industry, we expect competition to continue in…

NeoGenomics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NEO-DEBT-11210	Warrants outstanding: 650000	90%	xbrl warrant detail from xbrl 2016-12-31.
NEO-DEBT	Debt stack $408.5M	90%	Market cache reports total debt of $408.5M.
NEO-DEBT-11211	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.

NeoGenomics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NeoGenomics, Inc..

NeoGenomics, Inc. Ownership

Holder	Name	Confidence	Evidence
NEO-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 262 tracked holders.

NeoGenomics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
HOWL	Werewolf Therapeutics, Inc.	100.00	2
EXAS	Exact Sciences Corp	100.00	1	['customer', 'supplier']
IMNM	Immunome, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
GRAL	GRAIL, Inc.	100.00	2
TPST	Tempest Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
BNTC	Benitec Biopharma Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
TECX	Tectonic Therapeutic, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
ELVN	Enliven Therapeutics, Inc.	100.00	2
ABT	Abbott Laboratories	100.00	2
ATYR	aTyr Pharma, Inc.	100.00	2
BIAF	bioAffinity Technologies, Inc.	100.00	2
GH	Guardant Health, Inc.	100.00	1	['customer', 'supplier']

NeoGenomics, Inc. Supply Chain